Vaksin Covid-19 NDV-HXP-S
 | |
|---|---|
| Kemasan untuk versi Brasil dari NDV-HXP-S, ButanVac | |
| Deskripsi vaksin | |
| Penyakit target | SARS-CoV-2 |
| Jenis | ? |
| Data klinis | |
| Nama dagang | ButanVac (Brasil) |
| Kat. kehamilan | ? |
| Status hukum | ? |
| Rute | Intra-hidung |
| Pengenal | |
| Kode ATC | ? |
NDV-HXP-S (dikenal sebagai ButanVac[1] di Brasil) adalah sebuah kandidat vaksin COVID-19 yang dikembangkan oleh sebuah tim yang dipimpin oleh Jason McLellan di University of Texas at Austin,[2] bersama dengan kelompok dari Icahn School of Medicine at Mount Sinai dan National Institute of Allergy and Infectious Diseases Vaccine Research Center.[3] Pengembangannya dikoordinasikan oleh PATH Center for Vaccine Innovation and Access, dan UT Austin dan ISMMS mengaransemenkan perjanjian berlisensi bebas royalti dengan lab-lab dan perusahaan-perusahaan di 80 negara.
Referensi
- ^ Simões E, Fonseca P (March 26, 2021). "Brazil posts record 3,650 new COVID-19 deaths, unveils two homegrown vaccines". Reuters. Diakses tanggal 7 April 2021.
Earlier, Sao Paulo's Butantan biomedical institute said it will seek approval ... Butantan aims to produce 40 million doses of the Butanvac vaccine ... The vaccine was developed using a modified virus, which causes the Newcastle disease in birds ...
- ^ Cross R (20 July 2020). "What will it take to make an effective vaccine for COVID-19?". Chemical & Engineering News. 98 (28): 35–42. doi:10.1021/cen-09828-cover.
- ^ Zimmer C (April 5, 2021). "Researchers Are Hatching a Low-Cost Coronavirus Vaccine". The New York Times. Diakses tanggal 7 April 2021.
- l
- b
- s
Pandemi Covid-19
- SARS-CoV-2 (virus)
- Penyakit koronavirus 2019 (Covid-19)
Institusi | |||||||
|---|---|---|---|---|---|---|---|
| |||||||
Masalah | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| |||||||||
| |||||||
Tokoh | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||||||
Portal
Kategori
Commons
